Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018


Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1- Pipeline Review, H2 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Gastrointestinal, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Osteoarthritis, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bone Disorders, Breast Cancer, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Lung Adenocarcinoma, Metastatic Breast Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Pulmonary Hypertension, Scar, Solid Tumor, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma) and Wounds.

Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope